Latest news with #NewBiologicalEntity
&w=3840&q=100)
Business Standard
6 days ago
- Business
- Business Standard
Institutional buyers drive demand for Anthem Biosciences IPO; GMP up 26%
Anthem Biosciences IPO subscription status: Non-institutional investors (NIIs) were driving the demand for the initial public offering (IPO) of Anthem Biosciences on the final day of subscription. The participation from the qualified institutional buyers (QIBs), and retail investors was also encouraging as the public issue garnered bids for 48,76,15,180 equity shares against 4,40,70,682 on offer, resulting in an oversubscription of 11:06 times till 12:42 PM on Wednesday, July 16, showed the NSE data. Among the individual categories, NIIs have oversubscribed the category reserved for them by 27.08 times, followed by QIBs at 11.86 times, and retail investors at 3.80 imes. Anthem Biosciences IPO grey market premium (GMP) today The favourable sentiments were seen in the grey markets too, where the company's unlisted shares were exchanging hands at around ₹720 apiece, reflecting a grey market premium (GMP) of ₹150 per share or approximately 26.32 per cent above the upper end of the IPO price band of ₹570 apiece, according to the sources tracking grey market activities. Anthem Biosciences IPO review Analysts at Anand Rathi Research have assigned a subscribe rating to the issue, citing the company's potential to continue to grow its revenue and profitability ratios compared to its peers. Those at SBI Securities have recommended the investors to subscribe to the public issue for the long-term perspective, citing that the IPO is fairly priced while comparing with peers, along with a superior return and margin profile. Anthem Biosciences IPO details The ₹3,395.00 crore public issue of Anthem Biosciences comprises an entirely offer for sale (OFS) with promoters and shareholders divesting 59.6 million equity shares. The public issue is being offered in a price band of ₹540-570 per share, with a lot size of 26 shares. A retail investor can bid for a minimum of 1 lot or 26 and in multiples thereof, with a minimum investment of ₹14,820. As the subscription window closed today, the basis of allotment of Anthem Biosciences IPO shares is expected to be finalised on July 17, with shares credited to successful applicants' demat accounts on July 18. Anthem Biosciences shares are scheduled to list on the NSE and BSE tentatively on July 21, 2025. Kfin Technologies is acting as the registrar to the issue, while JM Financial is serving as the sole book-running lead manager. About Anthem Biosciences Anthem Biosciences is an innovation-led CRDMO (Contract Research Development and Manufacturing Organization) in India, offering end-to-end services across drug discovery, development, and manufacturing for both New Chemical Entity (NCE) and New Biological Entity (NBE). The company is among a select group of Indian players with integrated capabilities spanning New Chemical Entities (NCEs) and New Biological Entities (NBEs) across the drug discovery, development, and commercial manufacturing value chain.
&w=3840&q=100)
Business Standard
6 days ago
- Business
- Business Standard
Intuitional buyers drive demand for Anthem Biosciences IPO; GMP up 26%
Anthem Biosciences IPO subscription status: Non-institutional investors (NIIs) were driving the demand for the initial public offering (IPO) of Anthem Biosciences on the final day of subscription. The participation from the qualified institutional buyers (QIBs), and retail investors was also encouraging as the public issue garnered bids for 48,76,15,180 equity shares against 4,40,70,682 on offer, resulting in an oversubscription of 11:06 times till 12:42 PM on Wednesday, July 16, showed the NSE data. Among the individual categories, NIIs have oversubscribed the category reserved for them by 27.08 times, followed by QIBs at 11.86 times, and retail investors at 3.80 imes. Anthem Biosciences IPO grey market premium (GMP) today The favourable sentiments were seen in the grey markets too, where the company's unlisted shares were exchanging hands at around ₹720 apiece, reflecting a grey market premium (GMP) of ₹150 per share or approximately 26.32 per cent above the upper end of the IPO price band of ₹570 apiece, according to the sources tracking grey market activities. Anthem Biosciences IPO review Analysts at Anand Rathi Research have assigned a subscribe rating to the issue, citing the company's potential to continue to grow its revenue and profitability ratios compared to its peers. Those at SBI Securities have recommended the investors to subscribe to the public issue for the long-term perspective, citing that the IPO is fairly priced while comparing with peers, along with a superior return and margin profile. Anthem Biosciences IPO details The ₹3,395.00 crore public issue of Anthem Biosciences comprises an entirely offer for sale (OFS) with promoters and shareholders divesting 59.6 million equity shares. The public issue is being offered in a price band of ₹540-570 per share, with a lot size of 26 shares. A retail investor can bid for a minimum of 1 lot or 26 and in multiples thereof, with a minimum investment of ₹14,820. As the subscription window closed today, the basis of allotment of Anthem Biosciences IPO shares is expected to be finalised on July 17, with shares credited to successful applicants' demat accounts on July 18. Anthem Biosciences shares are scheduled to list on the NSE and BSE tentatively on July 21, 2025. Kfin Technologies is acting as the registrar to the issue, while JM Financial is serving as the sole book-running lead manager. About Anthem Biosciences Anthem Biosciences is an innovation-led CRDMO (Contract Research Development and Manufacturing Organization) in India, offering end-to-end services across drug discovery, development, and manufacturing for both New Chemical Entity (NCE) and New Biological Entity (NBE). The company is among a select group of Indian players with integrated capabilities spanning New Chemical Entities (NCEs) and New Biological Entities (NBEs) across the drug discovery, development, and commercial manufacturing value chain.
Time of India
08-07-2025
- Business
- Time of India
Anthem Biosciences IPO: Rs 3,395 crore IPO to open on July 14
The initial public offering (IPO) of Anthem Biosciences will open for subscription on Monday, July 14. The Bengaluru-based CRDMO player is planning to raise Rs 3,395 crore through the issue. The issue will conclude on Wednesday, July 16. About Anthem Biosciences IPO The IPO is an Offer for Sale (OFS) and comprises stake sale aggregating up to Rs 350 crores each by Ganesh Sambasivam and K Ravindra Chandrappa who are promoter selling shareholders. Up to Rs 1,325 crores will be offloaded by Viridity Tone LLP and up to Rs 320 crores by Portsmouth Technologies LLC (Investor Selling Shareholders). by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Free P2,000 GCash eGift UnionBank Credit Card Apply Now Undo It also includes stake sales of Rs 320 crores each by Malay J Barua, Rupesh N Kinekar and Satish Sharma, up to Rs 80 crore by Prakash Kariabettan and up to Rs 10 crore by K Ramakrishnan. About Anthem Biosciences Anthem's business comprises Contract Research, Development and Manufacturing Organization (CRDMO) services and the manufacture and sale of specialty ingredients. It offers a comprehensive, integrated and highly customizable range of CRDMO services across the New Chemical Entity (NCE) and New Biological Entity (NBE) lifecycles. The company claims to have a strong presence across various modalities, such as RNAi, ADC, peptides, lipids and oligonucleotides, and manufacturing techniques, such as flow chemistry, enzymatic processes, biocatalysis and fermentation, offering a broad range of technology capabilities for drug development. It also manufactures and sells complex specialized fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars. Live Events Ajay Bhardwaj (Chairman, MD & CEO), Ganesh Sambasivam (Whole-time Director and Chief Scientific Officer), K Ravindra Chandrappa (Whole-time Director and Chief Operating Officer) and Ishaan Bhardwaj (Vice President) are the Promoters of the company. The company, which was incorporated in 2006, has two operational manufacturing facilities in India, Unit I (Bommassandra) and Unit II (Harohalli), both in Karnataka, with an aggregate annual custom synthesis capacity of 270 kL and fermentation capacity of 142 kL, as of March 31, 2025. According to the RHP, the company is in the process of expanding its custom synthesis capacity at Unit II (Harohalli) by 130 kL as well as expanding its custom synthesis capacity by 25kL and fermentation capacity by 40kL by constructing Unit III (Neoanthem Lifesciences Private Limited, wholly-owned Subsidiary), both expected to be fully operational by the first half of Fiscal 2026. Post-expansion activities, the aggregate annual custom synthesis capacity and fermentation capacity is expected to increase to 425 kL and 182 kL, respectively. The fermentation capacity of 182 kL is expected to be more than six times the capacity of the second largest player in this industry, according to the F&S Report. Anthem Biosciences financials Its revenue from operations increased by 30% to Rs 1,844 crores in FY25 from Rs 1,419 crores in FY24. The PAT for the year ended March 31, 2025 was Rs 451 crores, a jump of 22.86% over FY24. Sai Life Sciences Limited, Syngene International Limited , Cohance Lifesciences Limited , (Formerly Suven Pharmaceuticals) and Divi's Laboratories Limited are the listed peers of Anthem Biosciences, as per its RHP. Anthem Biosciences lead managers The Book Running Lead Managers to the offer are JM Financial Limited , Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited and Nomura Financial Advisory and Securities (India) Private Limited. The equity shares are proposed to be listed on BSE and NSE.
